From GlobeNewswire: 2025-05-27 08:59:00

NurExone Biologic Inc. announces financial results for Q1 2025, with a net loss of US$1.68 million, compared to US$0.92 million in Q1 2024. The company raised C$480 thousand through a private placement and C$866 thousand through warrant exercises. NurExone is included in the 2025 TSX Venture 50™ list, showcasing its market performance and strategic advances.

NurExone establishes Exo-Top Inc., a U.S. subsidiary focusing on exosome production and commercialization. Additionally, the company raised C$2.3 million through a private placement in April 2025. ExoPTEN, NurExone’s lead therapy, is expected to enter first-in-human trials in 2026, showing promise in optic nerve and facial nerve repair. The company is advancing towards key clinical milestones and expanding its therapeutic pipeline.

CEO, Dr. Lior Shaltiel, highlights the functional recovery demonstrated by ExoPTEN across various injuries, emphasizing the company’s focus on building a robust foundation for upcoming trials. CFO, Eran Ovadya, mentions disciplined investment and financial results reflecting solid progress in clinical programs and infrastructure. The company remains committed to advancing towards key milestones in 2025.

NurExone Biologic Inc. is a biotech company focused on exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has shown promising preclinical data for treating spinal cord and optic nerve injuries. With strategic advancements and financial achievements, NurExone is poised to make significant strides in regenerative medicine and targeted drug delivery systems.



Read more at GlobeNewswire:: NurExone Biologic Inc. Announces First Quarter 2025